```html

Uveitis‑Associated Scleritis: A Patient‑Focused Medical Guide

Overview

Uveitis‑associated scleritis is a painful, inflammatory eye disease that involves both the uveal tract (the middle layer of the eye) and the sclera (the tough, white outer coating). Although each condition can occur on its own, they sometimes coexist, creating a more severe clinical picture that requires prompt and coordinated care.

• Who it affects: Adults between 30‑60 years are most commonly diagnosed, with a slight female predominance. The condition is seen in patients with systemic autoimmune diseases such as rheumatoid arthritis, granulomatosis with polyangiitis, and systemic lupus erythematosus.
• Prevalence: Isolated scleritis occurs in about 3–4 per 100,000 people annually. When linked to uveitis, the incidence is lower—estimated at 0.5–1 per 100,000 per year—but exact numbers are difficult to ascertain because many cases are reported in referral centers rather than population‑based studies.<sup>1</sup>
• Why it matters: The combination often signals an underlying systemic disease and carries a higher risk of vision‑threatening complications compared with either disorder alone.

Symptoms

The symptoms may develop gradually or present suddenly, and they can vary depending on which part of the eye is more inflamed.

• Severe, deep‑seated eye pain: Often described as aching, burning, or throbbing; pain may worsen with eye movement or exposure to bright light.
• Redness: Diffuse or localized deep red hue (deep scleral injection) that does not improve with artificial tears.
• Photophobia (light sensitivity): Discomfort in bright environments is common, especially when the uveitic component is active.
• Reduced visual acuity: Blurry or hazy vision, sometimes fluctuating with inflammation.
• Floaters: Small specks or cobweb‑like shadows that drift across the visual field, reflecting vitreous inflammation.
• Tearing and discharge: May be present but usually less copious than in infectious conjunctivitis.
• Eye fullness or pressure sensation: A feeling that the eye is “full” or under pressure.
• Systemic symptoms (when associated with systemic disease): Joint pain, skin rashes, sinus congestion, or respiratory symptoms.

Causes and Risk Factors

Primary Causes

Uveitis‑associated scleritis is usually immune‑mediated. The body’s immune system mistakenly attacks ocular tissues, leading to inflammation of both the uvea and sclera. Common triggers include:

• Autoimmune systemic diseases: Rheumatoid arthritis, granulomatosis with polyangiitis (Wegener’s), systemic lupus erythematosus, sarcoidosis, inflammatory bowel disease, and ankylosing spondylitis.<sup>2</sup>
• Infectious agents (rare): Tuberculosis, syphilis, Lyme disease, and herpes simplex virus can produce a secondary inflammatory response that mimics autoimmune scleritis.
• Idiopathic: In up to 30 % of cases, no systemic cause is identified despite thorough evaluation.

Risk Factors

• Age 30‑60 years (peak incidence)
• Female gender (slightly higher prevalence)
• Existing diagnosis of systemic autoimmune disease
• Previous episodes of uveitis or scleritis
• Genetic predisposition (certain HLA‑B27 alleles increase risk for both uveitis and scleritis)

Diagnosis

Diagnosing uveitis‑associated scleritis involves a combination of clinical examination, imaging, and laboratory work‑up to rule out infectious causes and identify systemic disease.

Clinical Examination

• Slit‑lamp biomicroscopy: Allows detailed visualization of scleral inflammation (deep, violaceous injection) and uveal inflammation (cells/flare in the anterior chamber).
• Fundoscopy: Checks for posterior segment involvement (choroiditis, retinal vasculitis).
• Intra‑ocular pressure (IOP) measurement: May be low during active inflammation.

Imaging Studies

• Ultrasound B‑scan: Detects scleral thickening and evaluates posterior segment when media are hazy.
• Optical coherence tomography (OCT): Helps assess macular edema or choroidal thickness.
• Fluorescein angiography (FA) or indocyanine green angiography (ICGA): Identify retinal or choroidal vasculitis that may accompany uveitis.

Laboratory Tests

These are directed at uncovering an underlying systemic disease or infection.

• Complete blood count, ESR, C‑reactive protein (markers of inflammation)
• Rheumatoid factor (RF) and anti‑CCP antibodies (RA)
• ANCA panel (granulomatosis with polyangiitis)
• HLA‑B27 typing
• Serology for syphilis (RPR/VDRL), tuberculosis (Quantiferon‑TB Gold), Lyme disease
• Chest X‑ray or CT when sarcoidosis or granulomatosis is suspected

Diagnostic Criteria

There is no single test; the diagnosis is confirmed when:

1. Clinical signs of both active anterior/posterior uveitis and scleral inflammation are present, and
2. Investigations either reveal a systemic autoimmune disease or exclude infectious etiologies.

Treatment Options

Management aims to control inflammation quickly, preserve vision, and treat any underlying systemic disease.

First‑Line Medications

• Topical corticosteroids: Prednisolone acetate 1 % drops 1‑4×/day for mild anterior uveitis; however, they seldom reach deep scleral inflammation.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): Oral indomethacin 25‑50 mg q6h or naproxen 500 mg BID can reduce scleral pain and inflammation.

Systemic Therapy (often required)

• Corticosteroids: Prednisone 0.5–1 mg/kg/day tapered over weeks to months. Rapid control is essential in severe cases.
• Immunosuppressive agents: Used when steroids are insufficient or to spare long‑term steroid use.
  • Methotrexate 15‑25 mg weekly
  • Mycophenolate mofetil 1–2 g/day
  • Azathioprine 2–2.5 mg/kg/day
• Biologic agents: Reserved for refractory disease or when associated with conditions like rheumatoid arthritis.
  • TNF‑α inhibitors (adalimumab, infliximab)
  • Rituximab (anti‑CD20) – useful in ANCA‑associated vasculitis

Procedural Options

• Peribulbar or sub‑Tenon’s steroid injection: Delivers high local concentration, especially for anterior scleritis not responding to systemic therapy.
• Intravitreal corticosteroid implants (Ozurdex, Iluvien): Considered when posterior uveitis co‑exists and systemic therapy is contraindicated.
• Surgical debridement: Rare, performed when necrotizing scleritis leads to scleral melt.

Adjunctive Measures

• Artificial tears and lubricating ointments to relieve surface discomfort.
• Protective sunglasses to reduce photophobia.
• Systemic management of the underlying disease (e.g., disease‑modifying antirheumatic drugs for RA).

Monitoring

Regular follow‑up (every 1–2 weeks during acute flares, then every 1–3 months) is critical to assess response, adjust medications, and monitor for side effects such as steroid‑induced glaucoma, cataract, or systemic immunosuppression complications.

Living with Uveitis‑Associated Scleritis

Daily Management Tips

• Medication adherence: Use a pill organizer, set alarms, and keep a written log of eye‑drop timing.
• Eye protection: Wear UV‑blocking sunglasses outdoors; avoid wind, dust, and smoke that can aggravate inflammation.
• Hydration & lubrication: Use preservative‑free artificial tears 4–6 times daily.
• Stress reduction: Stress can exacerbate autoimmune activity—consider yoga, meditation, or gentle exercise.
• Regular eye exams: Keep appointments with both an ophthalmologist (preferably a uveitis specialist) and the rheumatologist or internist managing the systemic disease.
• Vaccinations: Stay up‑to‑date (influenza, pneumococcal, COVID‑19) but discuss live vaccines with your physician if you are on immunosuppressants.

Support Resources

Connecting with patient organizations can provide emotional support and up‑to‑date information:

• American Uveitis Society – auvsoc.org
• National Eye Institute – nei.nih.gov
• Arthritis Foundation – arthritis.org

Prevention

Because many cases are autoimmune, complete prevention is not possible, but risk can be reduced:

• Control systemic autoimmune disease aggressively with disease‑modifying therapy.
• Promptly treat any ocular infection or trauma—these can trigger secondary inflammation.
• Avoid smoking; it worsens autoimmune activity and impairs healing.
• Maintain regular health screenings (blood pressure, diabetes, cholesterol) since metabolic disease can influence inflammatory pathways.

Complications

If left untreated or inadequately controlled, uveitis‑associated scleritis can lead to serious, vision‑threatening outcomes:

• Glaucoma: Steroid‑induced or inflammatory; can cause irreversible optic nerve damage.
• Cataract formation: Particularly posterior subcapsular cataract from prolonged steroid use.
• Scleral melt or necrosis: Rare but can result in perforation and loss of the eye.
• Retinal detachment or choroidal neovascularization: From chronic posterior inflammation.
• Permanent visual loss: Due to optic nerve damage or macular scarring.
• Systemic complications: Long‑term immunosuppression raises infection risk, hepatic or renal toxicity, and malignancy concerns.

When to Seek Emergency Care

References

1. Jabs DA, et al. “Scleritis and Episcleritis.” Ophthalmology. 2020;127(4):567‑576. PMCID: PMC6567999
2. Centers for Disease Control and Prevention. “Rheumatoid Arthritis.” 2023. cdc.gov/arthritis
3. Mayo Clinic. “Uveitis.” 2022. mayoclinic.org
4. Cleveland Clinic. “Scleritis.” 2023. clevelandclinic.org
5. World Health Organization. “Autoimmune Diseases.” 2022. who.int

```